News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kirin Brewery Co., Ltd. (KNBWY) And Astellas Pharma Inc. Enter Into Licensing Agreement On Immunosuppressive Fully Human Monoclonal Antibody



1/24/2007 12:04:16 PM

Tokyo, Jan 24, 2007 (JCN Newswire) - Kirin Brewery Company, Limited and Astellas Pharma Inc. announced today that they have entered into a license and collaborative research and development agreement under which Kirin and Astellas will exclusively collaborate in developing and marketing a fully human anti-CD40 antagonistic monoclonal antibody ("CD40 antagonistic mAb") worldwide.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES